Please try another search
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient’s own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States. The company is also developing various types of cell products, such as synergetic cell populations, neural cell precursors, and cardiomyocyte cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.
Name | Age | Since | Title |
---|---|---|---|
Alan B. Lumsden | - | - | Member of Scientific Advisory Board |
York N. Hsiang | - | 2020 | Member of Scientific Advisory Board |
Peter Alan Lacey | 67 | 2020 | Independent Chairman |
Loran Swanberg | - | 2020 | Independent Director |
Thomas A. Smeenk | 61 | 2019 | Co-Founder, President, CEO & Director |
Norman C. W. Wong | - | 2017 | Member of Scientific Advisory Board |
Kumar L. Hari | - | 2017 | Member of Scientific Advisory Board |
Sheila Copps | - | 2020 | Member of Board of Advisors |
David H. Tsubouchi | 71 | 2020 | Member of Board of Advisors |
Ronnie Allen Hershman | - | 2020 | Independent Director |
Ernst von Schwarz | - | 2022 | Member of Scientific Advisory Board |
Johannes Grillari | - | 2022 | Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review